Brain Amyloid Imaging — FDA Approval of Florbetapir F18 Injection
نویسندگان
چکیده
منابع مشابه
Brain amyloid imaging--FDA approval of florbetapir F18 injection.
n engl j med 367;10 nejm.org september 6, 2012 885 of disorders, some of which can be treated (e.g., severe depression or effects of medications) but others of which may signal the development of incurable dementias, such as Alzheimer’s disease. For these reasons, the development and improvement of diagnostic procedures — and neuroimaging procedures, in particular — that aid in characterizing c...
متن کاملTechnical Considerations in Brain Amyloid PET Imaging with 18F-Florbetapir.
Technical factors play a critical role in the production of best-quality amyloid PET images for interpretation. This article provides specific instructions and general technical information about PET brain scanning of β-amyloid neuritic plaques. The focus of tracer-specific information will be on (18)F-florbetapir (indications, contraindications, dosing, administration, uptake time, scanning ti...
متن کاملFlorbetapir F18 PET Amyloid Neuroimaging and Characteristics in Patients With Mild and Moderate Alzheimer Dementia.
BACKGROUND Clinical diagnosis of Alzheimer disease (AD) is challenging, with a 70.9%-87.3% sensitivity and 44.3%-70.8% specificity, compared with autopsy diagnosis. Florbetapir F18 positron emission tomography (FBP-PET) estimates beta-amyloid plaque density antemortem. METHODS Of 2052 patients (≥55 years old) clinically diagnosed with mild or moderate AD dementia from 2 solanezumab clinical t...
متن کاملUse of Florbetapir-PET for Imaging -Amyloid Pathology
Christopher M. Clark, MD Julie A. Schneider, MD Barry J. Bedell, MD, PhD Thomas G. Beach, MD, PhD Warren B. Bilker, PhD Mark A. Mintun, MD Michael J. Pontecorvo, PhD Franz Hefti, PhD Alan P. Carpenter, PhD Matthew L. Flitter, BA Michael J. Krautkramer, BS Hank F. Kung, PhD R. Edward Coleman, MD P. Murali Doraiswamy, MD Adam S. Fleisher, MD, MAS Marwan N. Sabbagh, MD Carl H. Sadowsky, MD Eric M....
متن کاملFDA drug approval summaries: fulvestrant.
Patients with hormone-sensitive breast cancer who have responded to tamoxifen may receive additional benefit from a second endocrine agent following progression or relapse after tamoxifen therapy. Fulvestrant (Faslodex((R)), ICI 182780, AstraZeneca Pharmaceuticals; Wilmington, Delaware) is a selective antagonist of estrogen designed to have no estrogenic effects. Lack of aqueous solubility led ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: New England Journal of Medicine
سال: 2012
ISSN: 0028-4793,1533-4406
DOI: 10.1056/nejmp1208061